Among PLS patient families, clinically asymptomatic heterozygous carriers demonstrated DPP1 activity reduced to only 13%–47% of controls, suggesting that PLS-like symptoms may only emerge when DPP1 inhibition exceeds 80%–90% (Albandar et al., 2012). The gene discussed is CTSC; the disease is Papillon-Lefevre disease.